Tumor Board Reviewing Treatment Considerations in Advanced Prostate Cancer Patient CasesSent on 26 March 2023
PSMA PET for Advanced Prostate Cancer, A Case-Based Tumor Board SeriesSent on 14 February 2023
Artificial Intelligence Transformative in Prostate Cancer Patient CareSent on 13 February 2023
Implications for Genetic Testing and Genomic Health Literacy in Clinical Management of Prostate CancerSent on 12 February 2023
Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer PatientsSent on 06 February 2023
Treatment Intensification in Metastatic Hormone-Sensitive Prostate CancerSent on 05 February 2023
PSMA PET Imaging in Clinical PracticeSent on 01 February 2023
Integrating the Use of Prostate Genomic Classifiers into Clinical Practice - A Clinical Pathway Approach for Prostate CancerSent on 30 January 2023
Beyond Genomics: AI Informing Decision Making in Prostate CancerSent on 23 January 2023
A Case-Based Tumor Board Series in PSMA PET for Advanced Prostate CancerSent on 20 January 2023
Treatment Intensification Strategies in Metastatic Castration-Sensitive Prostate Cancer: Triplets and MoreSent on 18 January 2023
Disparities and Trends in Prostate Cancer Incidence and MortalitySent on 15 January 2023
Can Biology Help Inform Treatment Decisions In the Management of mHSPC? Sent on 13 January 2023
MpMRI for Detection of Clinically Significant Prostate Cancer & PSMA PET/CT to Optimize Prostate Cancer Diagnosis Sent on 12 January 2023
The Effect of Metastasis-Directed Therapy on Oligometastatic Castration-Sensitive Prostate Cancer Outcomes Sent on 08 January 2023
Optimizing Multi-Disciplinary Care Teams for Radiopharmaceutical AdministrationSent on 06 January 2023
News and Noteworthy: Advancements in Metastatic Castration Resistant Prostate CancerSent on 04 January 2023
News and Note Worthy: The Use of Genomics in Prostate Cancer ManagementSent on 03 January 2023
PSMA PET CT Molecular Imaging Applied to the Prostate Cancer Tumor Board Series Sent on 02 January 2023
News and Noteworthy: Beyond PSMA - Novel Therapies in Prostate CancerSent on 28 December 2022
News and Noteworthy: Genomic Classifiers to Help Inform Personalized Treatment Decisions in Men with Prostate CancerSent on 27 December 2022
News and Noteworthy: Biological Difference Based on Race: Disparities Throughout the Spectrum of Prostate CancerSent on 26 December 2022
Experts Review 2022 Journal Club PublicationsSent on 21 December 2022
Real-World Data to Enhance Characterization of Advanced Prostate Cancer and Further Enable Precision OncologySent on 20 December 2022
Treatment Intensification Strategies in Advanced Prostate CancerSent on 19 December 2022
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic Castration-Resistant Prostate Cancer Sent on 18 December 2022
Approaches to Treatment Resistance in the Management of Castration-Resistant Prostate CancerSent on 14 December 2022
A Case-Based Tumor Board Series in PSMA PET for Advanced Prostate CancerSent on 13 December 2022
Using Liquid Biopsies in Clinical Practice to Inform Decision Making for Prostate Cancer CareSent on 13 December 2022
The Future of Radiopharmaceuticals in the Treatment of Prostate CancerSent on 29 November 2022
New Targets in Prostate CancerSent on 18 November 2022
Managing Contemporary mHSPC TreatmentSent on 16 November 2022
PSMA PET in the Care of Patients with Prostate Cancer - A Tumor Board SeriesSent on 15 November 2022
Association of PSA Screening Rates With Subsequent Metastatic Prostate Cancer Incidence and More Expert Led Journal ClubsSent on 10 November 2022
Prognostic Clinical Outcomes in Men with High-Risk Non-Metastatic and Metastatic Prostate Cancer - Findings from the STAMPEDE Trial PlatformSent on 01 November 2022
Tumor Board Reviewing PSMA PET in the Care of Prostate Cancer PatientsSent on 31 October 2022
Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate CancerSent on 21 October 2022
Optimizing Treatment of Patients with Bone Dominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)Sent on 19 October 2022
PSMA Theranostics and Treatment Sequencing in mCRPCSent on 18 October 2022
Combination Therapy with PARP Inhibitors in Advanced Prostate CancerSent on 17 October 2022
Prolonging PSA Progression-Free Survival in Biochemically Recurrent Prostate CancerSent on 16 October 2022
The Role of PSMA PET for Primary Staging In the Management of Prostate CancerSent on 12 October 2022
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Castration-Sensitive Prostate Cancer Sent on 11 October 2022
Combination Approaches for First-Line Therapy in Patients with mCRPCSent on 10 October 2022
Treatment Strategies for Advanced Prostate Cancer Presented in these Expert Led Journal Clubs Sent on 06 October 2022
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Sent on 06 October 2022
Trials in Progress in Prostate Cancer - Highlighting the Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in Metastatic Castration-Resistant Prostate CancerSent on 26 September 2022
Prostate Cancer Screening and Treatment Mechanisms - Journal Club HighlightsSent on 22 September 2022
Mental Health and Its Impact on Patients with GU MalignanciesSent on 20 September 2022
Emerging Therapies and Therapeutic Targets in Prostate CancerSent on 07 September 2022
  • Page of 7
Display #
Results 1 - 50 out of 314